Siemens’ new name, 6/16
June 2016—On May 4 Siemens Healthcare unveiled its new name, Siemens Healthineers. According to a company statement, the name “embodies the company’s pioneering spirit and engineering expertise in the healthcare industry.”
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Autoimmune thyroid disease tests, 6/16
June 2016—Thermo Fisher Scientific received 510(k) clearance for two new EliA IgG tests for detecting anti-thyroglobulin and anti-thyroid peroxidase autoantibodies in serum or plasma. The CLIA-moderate laboratory tests are performed on the fully automated Phadia 250, 2500, and 5000 laboratory systems.
IVD antibodies for IHC, 5/16
May 2016—Bio SB is offering 50 new antibodies for in vitro diagnostic applications. This generation of antibodies offers higher affinity, sensitivity, and specificity when compared with the previous generation of mouse monoclonal and polyclonal antibodies traditionally used in diagnostic immunohistochemistry applications. “Our new RBT and EP clones of rabbit monoclonal antibodies are unique reagents for cancer research and diagnostics,” Alfonso Heras, DVM, PhD, president and CEO of Bio SB, said in a statement. Among them are BRAF V600E, B7/H3,
PCR system, assay receive medical device license, 5/16
May 2016—Luminex received medical device licenses from Health Canada’s Therapeutic Products Directorate, Medical Devices Bureau, for the Aries System and Aries HSV 1&2 Assay; both were FDA cleared in October 2015 and were subsequently launched in the U.S. market.
3-D in vivo confocal microscope, 5/16
May 2016—MR Solutions’ 3-D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1,000 times, allowing researchers to examine cellular details within a live small animal, eliminating the need for a surgical biopsy.
Microinjection-ready Cas9 accelerate RNP, 5/16
May 2016—Horizon Discovery Group introduced its microinjection-ready Cas9 Accelerate Ribonucleoprotein. Cas9 Accelerate RNP maximizes gene-editing efficiency by enabling CRISPR …
Sysmex signs distribution agreement with Medline, 5/16
May 2016—Sysmex America has signed a nonexclusive distributor agreement with Medline Industries, a manufacturer and distributor of health care supplies.
Genomic test to predict prostate cancer progression, 5/16
ay 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.
FDA-cleared Graves’ disease assay, 5/16
May 2016—Siemens Healthcare Immulite 2000/2000 XPi TSI assay for the diagnosis of Graves’ disease is FDA cleared. The assay detects the presence of thyroid-stimulating antibodies only, is fully automated, and produces results in 65 minutes.
Mouse T- and B-lymphocyte kits, 5/16
May 2016—BD mouse T-lymphocyte and B-lymphocyte kits, protocols, and software templates for the BD Accuri C6 flow cytometer aim to simplify the identification of mouse T and B lymphocytes, their subsets, and their activation markers. The kits include fluorescent antibodies, buffer systems, and controls needed for acquisition and analysis.